Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S473000, C549S434000, C549S475000
Reexamination Certificate
active
07902255
ABSTRACT:
A γ-butyrolactone compound as shown in Formula (I) and pharmaceutical composition thereof:wherein X═N, O, S, Se; and A and B are selected from substituents having the following formula:wherein R1, R2, R3, R4, and R5are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group. The γ-butyrolactone compound and pharmaceutical composition thereof butyrolactone have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung cancer, malignant glioblastoma or colorectal carcinoma, and are cytotoxic with high specificity to inhibit Paclitaxel-resistant tumor cells at later stage of chemotherapy without any damage on normal cells.
REFERENCES:
Nishibe et al., Natural Medicines (Tokyo, Japan), 2002, vol. 56(1), p. 13-16 (abstract from STN search report).
Harn Horng-Jyh
Lin Shinn-Zong
Chu Yong
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Kim Dwight D.
Tzu Chi Buddhist General Hospital
LandOfFree
γ-butyrolactone compound and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with γ-butyrolactone compound and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and γ-butyrolactone compound and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663378